Ethical issues in child psychopharmacology research and practice: Emphasis on preschoolers

Psychopharmacology

Volumn 191, Issue 1, 2007, Pages 15-26

  Spetie, Lacramioara ^a   Arnold, L Eugene ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

ADHD; Ethics; Preschoolers; Psychopharmacology

Indexed keywords

ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT; PHENOBARBITAL; PSYCHOSTIMULANT AGENT; SEROTONIN UPTAKE INHIBITOR;

AGITATION; AKATHISIA; BEHAVIOR DISORDER; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITIVE DEFECT; DECISION MAKING; DRUG EFFICACY; DRUG SAFETY; EMOTIONAL DISORDER; ETHICS; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; FOOD AND DRUG ADMINISTRATION; HEART DISEASE; HUMAN; HYPERPROLACTINEMIA; HYPOMANIA; IRRITABILITY; LEGAL ASPECT; MANIA; MEDICAL RESEARCH; MENTAL HEALTH; MENTAL HEALTH CARE; METABOLIC SYNDROME X; MUSCLE HYPOTONIA; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHIATRY; PSYCHOPHARMACOLOGY; PSYCHOSIS; PULMONARY HYPERTENSION; REVIEW; RISK ASSESSMENT; SHIVERING; SIDE EFFECT; SUDDEN DEATH; SUICIDAL BEHAVIOR; TARDIVE DYSKINESIA; WEIGHT GAIN;

CHILD PSYCHOLOGY; CHILD, PRESCHOOL; CLINICAL TRIALS; ETHICS, CLINICAL; ETHICS, MEDICAL; HUMANS; MENTAL DISORDERS; PATIENT SELECTION; PRACTICE GUIDELINES; PSYCHOPHARMACOLOGY; PSYCHOTROPIC DRUGS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 33847128768     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-006-0685-8     Document Type: Review

References (68)

1. American Academy of Pediatrics - Committee of Drugs (1995) Guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations (RE9503) 95:286-294
2. Anderson GM (2004) Peripheral and central neurochemical effects of the selective serotonin reuptake inhibitors in humans and nonhuman primates: assessing bioeffect and mechanism of action. Int J Dev Neurosci 22:397-404
3. Ansorge MS, Zhou M, Lira A, Hen R, Gingrich JA (2004) Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science 306(5697):879-881 (Oct 29)
4. Arnold LE (2002) Treatment Alternatives for attention-deficit/ hyperactivity disorder. In: Jensen PS, Cooper J (eds) Attention deficit hyperactivity disorder: state of the science; best practices. Civic Research Institute, Kingston, NJ
5. Arnold L, Stoff D, Cooke E, Cohen DJ, Wright CB, Kruesi M, Hattab J, Arnold LE (1999) Treatment alternatives for attention-deficit/hyperactivity disorder (ADHD). J Atten Disord 3:30-48
6. Beauchamp TL, Childress JF (1994) Principles of biomedical ethics. Oxford Univ. Press, Oxford
7. Beck J, Azari E (1998) FDA, Off-label drug use, and informed consent: debunking myths and misconceptions. Food Drug Cosmet Law J 53:71-104
8. Bor W, Sanders M, Markie-Dadds C (2002) The effects of the Triple P Positive parenting program on preschool children with cooccurring disruptive behavior and attentional/hyperactive difficulties. J Abnorm Child Psychol 30:571-587
9. Carrey NJ, Dursun S, Clements R, Renton K, Waschbusch D, MacMaster FP (2002) Noradrenergic and serotonergic neuroendocrine responses in prepubertal, peripubertal, and postpubertal rats pretreated with desipramine and sertraline. J Am Acad Child Adolesc Psych 41:999-1006
10. Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, Mitchell AA (2006) Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. New Engl J Med 354(6):579-587
11. Chesney RW (2005) Children as clinical research subjects. J Pediatr 146:579-580 (May)
12. Cissoko H, Swortfiguer BG, Jonville-Bera AP, Autret-Leca E (2005) Neonatal outcome after exposure to selective reuptake inhibitors late in pregnancy. Arch Pediatr 12:1081-1084
13. Correll C, Carlson HE (2006) Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psych 45(7):771-791
14. Department of Health and Human Services-2000-Report of the Surgeon General's Conference on Children's Mental Health: a National Action Agenda
15. Deveaugh-Geiss J, March J, Shapiro M, Andreason P, Emslie G, Ford L, Greenhill L, Murphy D, Prentice E, Roberts R, Silva S, Swanson JM, Van Zwieten-Boot B, Vitiello B, Wagner KD, Mangum B (2006) Child and adolescent psychopharmacology in the New Millenium: a workshop for academia, industry, and government. J Am Acad Child Adolesc Psych 45(3):261-270
16. FDA (2001) FDA ignores Helsinki Declaration's new thinking on placebo trials. FDA week, Feb 9
17. Food and Drug Administration (1997) Modernization act of 1997. 21 USC 321
18. Gordon B, Prentice E, Anderson J (2000) Conflict between research design andminimization of risks in pediatric research. IRB 22(3):1-6
19. Grady C (2005) Payment of clinical research subjects. J Clin Invest 115(7):1681-1687 (July 2005)
20. Greenhill L, Jensen P, Abikoff H, Blumer JL, DeVeaugh-Geiss J, Fisher C, Hoagwood K, Kratochvil CJ, Lahey B, Laughren T, Leckman J, Petti TA, Pope K, Shaffer D, Vitiello B, Zeanah, C (2003) Developing strategies for psychopharmacological studies in preschool children. J Am Acad Child Adolesc Psych 42:406-414 (April)
21. Jensen PS (1998) Ethical and pragmatic issues in the use of psychotropic agents in young children. Can J Psychiatry 43:585-588
22. Kazdin AE, Wassell G (2000) Therapeutic changes in children, parents, and families resulting from treatment of children with conduct problems. J Am Acad Child Adolesc Psych 39:414-420
23. Keenan K, Wakschlag LS (1998) More than the terrible twos: the nature and severity of behavior problems in clinic-referred preschool children. J Abnorm Child Psychol 28(1):33-46
24. Kollins SH, Greenhill L (2006) Evidence base for the use of stimulant medication in preschool children with ADHD. Infants Young Child 19(2):132-141
25. Kopelman LM (2004) Minimal risk as an international ethical standard in research. J Med Philos 29(3):351-378
26. Kratochvil CJ, Vitiello B, Walkup J, Emslie G, Waslick BD, Weller EB, Burke WJ, March JS (2006) Selective serotonin reuptake inhibitors in pediatric depression: Is the balance between benefits and risks favorable? J Child Adolesc Psychopharmacol 16(1/2):11-24
27. Kwan P, Brodie MJ (2001) Neuropsychological effects of epilepsy and antiepileptic drugs. Lancet 357:216-222
28. Lahey BB, Pelham WE, Stein MA, Loney J, Trapani C, Nugent K, Kipp H, Schmidt E et al (1998) Validity of DSM-IV attention-deficit/hyperactivity disorder for younger children. J Am Acad Child Adolesc Psych 37(7):695-702
29. Lehrman NS, Sharav VH (1997) Ethical problems in psychiatric research. J Mental Health Adm 24:227-250
30. March J, Beiderman J, Wolkow R, Safferman A, Mardekian J, Cook E, Cutler N, Dominquez R, Feruson J, Muller B, Riesenberg R, Rosenthal R, Sallee F, Wagner K, Steiner H (1998) Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. J Am Med Assoc 280(20):1752-1756
31. March J, Kratochvil C, Clarke G, Beardslee W, Derivan A, Emslie G, Green E, Heiligenstein J, Hinshaw S, Hoagwood K, Jensen P et al (2004) AACAP 2002 research forum: placebo and alternatives to placebo in randomized controlled trials in pediatric psychopharmacology. J Am Acad Child Adolesc Psych 43(8):1046-1056 (August)
32. Martin A, Young C, Leckman JF, Mukonoweshuro C, Rosenheck R, Leslie D (2004) Age effects on antidepressant-induced manic conversion. Arch Pediatr Adolesc Med 158(8):773-780
33. Minde K (1998) The use of psychotropic medications in preschoolers: some recent developments. Can J Psychiatry 43:571-575
34. Misri S, Reebye P, Kendrick K, Carter D, Ryan D, Grunau RE, Oberlander TF (2006) Internalizing behaviors in 4-year-old children exposed in utero to psychotropic medications. Am J Psychiatr 163(6):1026-1032 (June)
35. National Archives and Records Administration (1991) 45 Code of Federal Regulations (CFR). Subtitle A, part 46, Subpart D
36. National Archives and Records Administration (1998) 21 CFR parts 201, 312, 314, and 601 - FDA. Pediatric patients regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products; proposed rule (DOCKET no. 97N-0165) RIN 0910-AB20
37. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research (1979) The Belmont report: ethical principles and guidelines for the protection of human subjects of research. Fed Regist 44(76):23192-23197
38. National Institutes of Health (1998) Policy and guidelines on the inclusion of children as participants in research involving human subjects, March
39. NIMH (2000a) NIMH research forum. Recommended strategies for developing and implementing psychopharmacologic studies in preschool children. American academy of child and adolescent psychiatry 47th annual meeting, Oct. 25, 2000. Jointly sponsored by National Institute of Mental Health
40. NIMH (2000b) NIMH Workshop on Long-Term Drug Safety (Research Units in Pediatric Psychopharmacology, RUPP) - Sept. 25. NIMH Neurosciences Center, Rockville, MD
41. Nulman I, Rovet J, Stewart DE, Wolpin J, Gardner HA, Theis JGW, Kulin N, Koren G (1997) Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 336:258-262
42. Nulman I, Rovet J, Stewart DE, Wolpin J, Pace-Asciak P, Shuhaiber S, Koren G (2002) Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 159:1889-1895
43. Olfson M, Shaffer D, Marcus SC, Greenberg T (2003) Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry 60:978-982
44. Reid MJ, Webster-Stratton C, Baydar N (2004) Halting the development of conduct problems in head start children: the effects of parent training. J Clin Child Adolesc Psychol 33(2):279-291 (June)
45. Riddle M, Reeve E, Yaryura-Tobias J, Yang H et al (2001) Fluvoxamine for children and adolescents with obsessive compulsive disorder: a randomized controlled multicenter trial. J Am Acad Child Adolesc Psych 40(2):222-229
46. Roberts LW, Roberts B (1999) Psychiatric research ethics: an overview of evolving guidelines and current ethical dilemmas in the study of mental illness. Biol Psychiatry 46:1025-1038
47. Roberts LW, Warner TD, Brody JL (2000) Perspectives of patients with schizophrenia and psychiatrists regarding ethically important aspects of research participation. Am J Psychiatry 157:67-74
48. Shah S, Whittle A, Wilfond B, Gensler G, Wendler D (2004) Research in children: assessing risks and benefits. Pediatr Res 56(2):165-166
49. Shaw DS, Dishion TJ, Supplee L, Gardner F, Arnds K (2006) Randomized trial of a family-centered approach to the prevention of early conduct problems: 2-year effects of the family check-up in early childhood. J Consult Clin Psychol 74(1):1-9 (Feb)
50. Sivojelezova A, Shuhaiber S, Sarkissian L, Einarson A, Koren G (2005) Citalopram use in pregnancy: prospective comparative evaluation of pregnancy and fetal outcome. Am J Obstet Gynecol 193:2004-2009
51. Solyom AE, Moreno JD (2005) Protection of children and adolescents in psychiatric research: an unfinished business. HEC Forum 17 (3):210-226
52. Streyhorn JM, Weidman CS (1989) Reduction of attention deficit and internalizing symptoms in preschoolers through parent-child interaction training. J Am Acad Child Adolesc Psych 28:888-896
53. Twomey JG (2000) Ethical implications of pediatric drug research policy initiatives. IRB pp 2-7 (March-April)
54. US FDA (2004a) Public health advisory. Worsening depression and suicidality in patients being treated with antidepressant medications. March 22, 2004. Available at http://www.fda.gov/cder/drug/antidepressants/ AntidepressanstPHA.htm
55. US FDA (2004b) Public health advisory. Suicidality in children and adolescents being treated with antidepressant medications. October 15, 2004. Available at http://www.fda.gov/cder/drug/antidepressants/SSRIPHA200410.htm
56. Vitiello B (1998) Pediatric psychopharmacology and the interaction between drugs and the developing brain. Can J Psychiatry 43:582-584
57. Vitiello B (2001a) Long term effects of stimulant medications on the brain: possible relevance to the treatment of attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 11:25-34
58. Vitiello B (2001b) Psychopharmacology for young children: clinical needs and research opportunities. Pediatrics 108:983-989
59. Vitiello B (2003) Ethical considerations in psychopharmacological research involving children and adolescents. Psychopharmacology 171:86-91
60. Wadman M (1998) Ethical protection for subjects could stifle psychiatric research. Nature 394:713 (Aug. 20)
61. Wasserman GA, Miller LS (1998) The prevention of serious and violent juvenile offending. In: Loeber R, Farrington DP (eds) Serious and violent juvenile offenders: Risk factors and successful interventions. Sage, Thousand Oaks, CA, pp 197-247
62. Webster-Stratton C, Reid MJ, Hammond M (2004) Treating children with early-onset conduct problems: intervention outcomes for parent, child, and teacher training. J Clin Child Adolesc Psychol 33(1):105-124 (March)
63. Wegerer V, Moll GH, Bagli M, Rothenberger A, Ruther E, Huether G (1999) Persistently increased density of serotonin transporters in the frontal cortex of rats treated with fluoxetine during early juvenile life. J Child Adolesc Psychopharmacol 9:13-24
64. World Medical Association (1964) Declaration of Helsinki IV, 18th world medical assembly. Amended Hong Kong, Sept 1989. Council for international organizations of medical sciences (CIOMS). Geneva 1993
65. World Medical Association (2000) Declaration of Helsinki, ethical principles for medical research involving human subjects, adopted by the 52nd World Medical Association General Assembly, Edinburgh, Scotland, October
66. World Medical Association (2001) Declaration of Helsinki, note of clarification on placebo-controlled trials. World Medical Association, Newsletter, October
67. Yan EG, Munir KM (2004) Regulatory and ethical principles in research involving children and individuals with developmental disabilities. Ethics Behav 14(1)
68. Young SN, Annable L (1997) The use of placebos in psychiatry: a response to the draft document prepared by the tri-council working group. A position paper of the Canadian College of Neuropsychopharmacology. J Psychiatry Neurosci 21:354-359